Ypsomed Holding AG

Ypsomed Holding AG is a Swiss-based public company specializing in the development and manufacturing of medical devices for self-medication, with a core focus on injection and infusion systems. Serving as the parent of the Ypsomed Group, it provides solutions primarily used in the treatment of diabetes, growth disorders, infertility, and other clinical indications. The company operates two main business segments: Ypsomed Delivery Systems, which partners with pharmaceutical and biotech firms to supply advanced injection solutions such as pens, autoinjectors, and wearable injectors; and Ypsomed Diabetes Care, which delivers diabetes management devices directly to patients, hospitals, and pharmacies under the mylife Diabetescare brand. With over 2,800 employees and a global operational footprint, Ypsomed Holding AG plays a significant role in enabling patient-centric therapies and advancing technologies for self-administration of medications, making it a key partner for both healthcare providers and the pharmaceutical industry worldwide.